Nexus Pharmaceuticals Launches New Cyclophosphamide Injection to Expand Cancer Treatment Access

Nexus Pharmaceuticals, LLC has announced the launch of Cyclophosphamide Injection, a critical chemotherapy medication designed to sluggish the growth of cancer cells. Now available in ready-to-dilute multiple-dose vials, this launch aims to provide healthcare providers with more streamlined options for delivering essential oncology treatments.

Understanding Cyclophosphamide Injection

Cyclophosphamide is a chemotherapy drug used to treat various types of cancer. It works by slowing the growth of malignant cells, making it a cornerstone in many cancer treatment regimens. The new offering from Nexus Pharmaceuticals is the first AP Rated Generic to Dr. Reddy’s, ensuring that providers have access to high-quality, dependable alternatives for patient care.

Available Formulations and Specifications

To accommodate different dosing requirements, Nexus Pharmaceuticals is offering the injection in two specific fill sizes:

• 500 mg/2.5 mL (Unit of Sale NDC 14789-0125-05)
• 1 gram/5 mL (Unit of Sale NDC 14789-0126-05)

These formulations are provided in ready-to-dilute multiple-dose vials, which helps reduce labor intensity and streamlines the preparation process in clinical settings.

Improving Access to Specialty Medications

Nexus Pharmaceuticals specializes in the development of hard-to-manufacture specialty and generic drugs. By transforming complex molecules into high-quality medicines, the company focuses on filling unmet medical needs.

Stephen Kim, CEO of Nexus Pharmaceuticals, emphasized that bringing Cyclophosphamide to market is part of a broader commitment to expand access to critical treatments that both patients and healthcare providers rely on daily. The company’s goal is to make these life-saving options easier to use and more dependable where they’re needed most.

Critical Safety and Handling Requirements

Because Cyclophosphamide Injection is classified as a hazardous drug, it requires strict adherence to safety protocols. Healthcare professionals must exercise caution during handling and preparation, following all applicable special handling and disposal procedures to ensure safety.

Key Takeaways for Healthcare Providers

• Product Status: Now available as an AP Rated Generic.
• Format: Ready-to-dilute multiple-dose vials.
• Indications: Chemotherapy to slow cancer cell growth.
• Safety: Classified as a hazardous drug. requires special handling.
• Ordering: Available through wholesalers or via phone at (888) 806-4606.

Frequently Asked Questions

What makes this version of Cyclophosphamide different?

This version is a ready-to-dilute formulation, which is designed to be less labor-intensive for providers compared to traditional preparations. It is also the first AP Rated Generic to Dr. Reddy’s.

Who manufactures this injection?

The product is manufactured by Nexus Pharmaceuticals, LLC, a US-based healthcare company based in Lincolnshire, Illinois.

How can providers order the medication?

Providers can place orders through their established wholesalers or contact Nexus Pharmaceuticals directly at (888) 806-4606.

Looking Forward

The introduction of these ready-to-dilute vials represents a step toward reducing the operational burden on oncology wards and pharmacies. As Nexus Pharmaceuticals continues to target difficult-to-formulate molecules, the healthcare industry can expect more streamlined delivery systems for critical specialty medications.